159 related articles for article (PubMed ID: 38344867)
21. Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety.
Minichmayr IK; Karlsson MO; Jönsson S
Pharm Res; 2021 Apr; 38(4):593-605. PubMed ID: 33733372
[TBL] [Abstract][Full Text] [Related]
22. UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: A meta-analysis.
Yang Y; Zhou M; Hu M; Cui Y; Zhong Q; Liang L; Huang F
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e479-e489. PubMed ID: 29932297
[TBL] [Abstract][Full Text] [Related]
23. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
Wang Y; Shen L; Xu N; Wang JW; Jiao SC; Liu ZY; Xu JM
World J Gastroenterol; 2012 Dec; 18(45):6635-44. PubMed ID: 23236239
[TBL] [Abstract][Full Text] [Related]
24. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM
J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039
[TBL] [Abstract][Full Text] [Related]
25. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.
Glimelius B; Garmo H; Berglund A; Fredriksson LA; Berglund M; Kohnke H; Byström P; Sørbye H; Wadelius M
Pharmacogenomics J; 2011 Feb; 11(1):61-71. PubMed ID: 20177420
[TBL] [Abstract][Full Text] [Related]
26. Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients.
Karas S; Etheridge AS; Nickerson DA; Cox NJ; Mohlke KL; Cecchin E; Toffoli G; Mathijssen RHJ; Forrest A; Bies RR; Innocenti F
Br J Cancer; 2022 Mar; 126(4):640-651. PubMed ID: 34703007
[TBL] [Abstract][Full Text] [Related]
27. Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients.
Atasilp C; Chansriwong P; Sirachainan E; Reungwetwattana T; Chamnanphon M; Puangpetch A; Wongwaisayawan S; Sukasem C
Drug Metab Pharmacokinet; 2016 Feb; 31(1):90-94. PubMed ID: 26830078
[TBL] [Abstract][Full Text] [Related]
28. Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms.
Deng B; Jia L; Tan H; Lou Y; Li X; Li Y; Yu L
J Tradit Chin Med; 2017 Feb; 37(1):35-42. PubMed ID: 29956901
[TBL] [Abstract][Full Text] [Related]
29. Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.
Ishida H; Fujita K; Akiyama Y; Sunakawa Y; Yamashita K; Mizuno K; Miwa K; Kawara K; Ichikawa W; Ando Y; Saji S; Sasaki Y
Jpn J Clin Oncol; 2011 May; 41(5):617-23. PubMed ID: 21310730
[TBL] [Abstract][Full Text] [Related]
30. ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.
Li M; Seiser EL; Baldwin RM; Ramirez J; Ratain MJ; Innocenti F; Kroetz DL
Pharmacogenomics J; 2018 Jan; 18(1):35-42. PubMed ID: 27845419
[TBL] [Abstract][Full Text] [Related]
31. Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.
Shulman K; Cohen I; Barnett-Griness O; Kuten A; Gruber SB; Lejbkowicz F; Rennert G
Cancer; 2011 Jul; 117(14):3156-62. PubMed ID: 21287524
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3.
Iwata H; Umeyama Y; Liu Y; Zhang Z; Schnell P; Mori Y; Fletcher O; Marshall JC; Johnson JG; Wood LS; Toi M; Finn RS; Turner NC; Bartlett CH; Cristofanilli M
Oncologist; 2021 Jul; 26(7):e1143-e1155. PubMed ID: 33955129
[TBL] [Abstract][Full Text] [Related]
33. UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan.
Ferraldeschi R; Minchell LJ; Roberts SA; Tobi S; Hadfield KD; Blackhall FH; Mullamitha S; Wilson G; Valle J; Saunders M; Newman WG
Pharmacogenomics; 2009 May; 10(5):733-9. PubMed ID: 19450125
[TBL] [Abstract][Full Text] [Related]
34. Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk.
Hu ZY; Yu Q; Pei Q; Guo C
Clin Cancer Res; 2010 Aug; 16(15):3832-42. PubMed ID: 20562211
[TBL] [Abstract][Full Text] [Related]
35. The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis.
Chen YJ; Hu F; Li CY; Fang JM; Chu L; Zhang X; Xu Q
Biomarkers; 2014 Feb; 19(1):56-62. PubMed ID: 24308720
[TBL] [Abstract][Full Text] [Related]
36. UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients.
Peng H; Duan Z; Pan D; Wen J; Wei X
Clin Lab; 2017 Sep; 63(9):1339-1346. PubMed ID: 28879724
[TBL] [Abstract][Full Text] [Related]
37. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2009 Jan; 11(1):15-20. PubMed ID: 19125128
[TBL] [Abstract][Full Text] [Related]
38. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.
Sun W; O'Dwyer PJ; Finn RS; Ruiz-Garcia A; Shapiro GI; Schwartz GK; DeMichele A; Wang D
J Clin Pharmacol; 2017 Sep; 57(9):1159-1173. PubMed ID: 28419480
[TBL] [Abstract][Full Text] [Related]
39. Association of UGT1A1*6 polymorphism with irinotecan-based chemotherapy reaction in colorectal cancer patients: a systematic review and a meta-analysis.
Zhu X; Ma R; Ma X; Yang G
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32936306
[TBL] [Abstract][Full Text] [Related]
40. Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan.
Lu YY; Huang XE; Wu XY; Cao J; Liu J; Wang L; Xiang J
Asian Pac J Cancer Prev; 2014; 15(7):3335-41. PubMed ID: 24815493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
